Adjuvant nivolumab

DRUG2 trials

Sponsors

Universitätsklinikum Hamburg-Eppendorf, The Netherlands Cancer Institute

Conditions

Head and Neck CancerMalignant Melanoma Stage III

Phase 3

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Universitätsklinikum Hamburg-EppendorfHead and Neck Cancer

Start: 2018-08-21End: 2024-05-31Target: 276Updated: 2023-05-23

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruitingNCT04949113

The Netherlands Cancer InstituteMalignant Melanoma Stage III

Start: 2021-07-08End: 2028-12-19Updated: 2024-03-08

Related Papers

Missing data and missed opportunities: Inability to perform secondary analysis of prospective randomized control trials due to missing general anesthesia data.

Journal of Clinical Oncology2025-05-28

Management of Localized Melanoma in the Anti-PD-1 Era.

2024-06-062 citations

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Journal of Clinical Oncology2024-06-0521 citations

Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

Journal of Clinical Oncology2024-06-052 citations

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

New England Journal of Medicine2024-06-02359 citations

The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.

Journal of Clinical Oncology2024-06-012 citations

Neo-Adjuvant Therapy for Metastatic Melanoma

Cancers2024-03-224 citations

Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.

2023-04-2758 citations

The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.

Journal of Clinical Oncology2022-06-0145 citations

Phase III Study of Nivolumab Alone or Combined with Ipilimumab as Immunotherapy Versus Standard of Care in Resectable Head and Neck Squamous Cell Carcinoma

Future Oncology2020-09-0931 citations

Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy.

Journal of Clinical Oncology2019-05-202 citations